| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Biotechnology (IBB) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Biotechnology sector is positive (overall 1.4, positive 4.8, negative -3.4) on 20251118. The forces of Sector Price Trend (1.8), Valuation Sentiment (1.2), Sentiment towards Fundamentals (1), and Option Speculation (0.75) will drive up the price. The forces of Price Level (-0.5), Broad Market Trend (-1.4), and Market Risk Prefrence (-1.5) will drive down the price. 'Range trade' is the preferred trading strategy. The price likely reaches the lower bound of the range when hourly RSI reaches zero. The total negative sentiment score -3.4 setups for a powerful pullback when all negative forces work together (the positive forces hibernate) triggered by negative news events or a overbought condition. The swing to upside will be significant considering the high positive sentiment forces (4.8). The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on IBB trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Market Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-18 | 0% | 0.1% | 166.47 | 97 | 0.73% | 0.62% | 1.8 | 1.4 | 1 | 6.3 |
| 2025-11-17 | 0% | 0.3% | 165.26 | 96 | 0.65% | 0.5% | 2.2 | 2 | 1 | 8 |
| 2025-11-16 | 0% | 0.3% | 1.6 | 4.5 | 1.4 | 8 | ||||
| 2025-11-15 | 0% | 0.3% | 1.6 | 5 | 1.6 | 0 | ||||
| 2025-11-14 | 1% | 0.4% | 164.19 | 96 | 0.53% | 0.31% | 1.6 | 5 | 1.6 | 7.1 |
| 2025-11-13 | 0% | 0.3% | 163.32 | 95 | -0.99% | 0.38% | 1 | 4.9 | 1.7 | 7 |
| 2025-11-12 | 0% | 0.3% | 164.96 | 115 | 0.49% | 0.5% | 2.9 | 6.4 | 1.2 | 5 |
| 2025-11-11 | 1% | 0.4% | 164.15 | 123 | 2.91% | 0.38% | 1.9 | 5.9 | 1.5 | 4.5 |
| 2025-11-10 | 0% | 0.3% | 159.51 | 89 | 1.13% | 0.19% | 0.5 | 5.9 | 1 | 5 |
| 2025-11-09 | 0% | 0.4% | -0.6 | -1.9 | 0.9 | 0 | ||||
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| IBB Behaviors |
| ● Biotechnology (24%): The directional probability for IBB is 10% from last trading session on Mon. Nov 17, 2025. Both emotion level 5.3 is much higher than sentiment level 1.7 on Tue. Nov 18, 2025. Biotechnology (IBB) is attracting noticeable market attention on Tue. Nov 18, 2025. IBB is likely to move higher on any positive news, and recover from any dips of negative news. There's a likelihood of pullback since the IBB price was out of Bollinger upper band at the close of last trading session. When the price move is against the technical setup, sentiment and emotion, it's a sign of trend reversal. |
| 1 (5) China Ramps Up Experiments on Animals to Help Win Biotech Race On today’s Big Take Asia podcast we look at cutting-edge experiments on large animals in China in a bid to develop new drugs. (https://www.bloomberg.com/) Tue. Nov 18, 2025 | |
| 2 (7) Why biotech and drug stocks are on the mend even though the rest of the market is hurting Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away. (https://www.marketwatch.com/) Tue. Nov 18, 2025 | |
| 3 (7) Top 3 Biotech Stocks Capitalizing on the AI Revolution Market Analysis by covering: Eli Lilly and Company, Novo Nordisk A/S, Relay Therapeutics Inc, Neumora Therapeutics Inc. Read 's Market Analysis on Investing.com (https://www.investing.com/) Tue. Nov 18, 2025 | |
| 4 (8) Deal With Eli Lilly Propels Founder Of Korean Biotech Firm Into Billionaire Ranks South Korea’s newest billionaire is Lee Sang-hoon, founder of ABL Bio, after it struck a $2.6 billion licensing and joint research deal with Eli Lilly. (https://www.forbes.com/) Mon. Nov 17, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA